# Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer

> **NCT01589861** · PHASE1,PHASE2 · TERMINATED · sponsor: **Institut Paoli-Calmettes** · enrollment: 24 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** BKM120 + lapatinib

## Key facts

- **NCT ID:** NCT01589861
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-12
- **Primary completion:** 2017-10-10
- **Final completion:** 2017-10-10
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Drug development withdrawn
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01589861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01589861, "Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01589861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*